ACAD Stock Recent News
ACAD LATEST HEADLINES
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentat.
Shares of Acadia Pharmaceuticals surged after the Court granted a summary judgment in the Nuplazid patent case in its favor. The positive outcome removes an important legal overhang on ACAD stock and further share price advancements can be driven by Daybue's commercial success. Daybue continued to exceed expectations with a Q3 net sales beat and a strong Q4 outlook.
Acadia's Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million in the first six months, indicating significant market potential. Acadia's financials are robust with rising net product sales and a strong current ratio, but increasing operating expenses and net losses. Market confidence in Acadia is moderate, with high institutional ownership and insider buying, but mixed stock momentum.
Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.
Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
Here is how Acadia Pharmaceuticals (ACAD) and Medpace (MEDP) have performed compared to their sector so far this year.
Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments.
Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.